BioSpace News Archive

Medicure Inc. reported its results from operations for the quarter ended June 30, 2018.

Inc. magazine today revealed that Akervall Technologies is No. 2318 on its 37th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies.

CathWorks announced that its FAST-FFR trial is fully enrolled ahead of schedule.

IntriCon Corporation announced that it has priced an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $55.00 per share.

nited American Healthcare Corporation (OTC:UAHC) (the “Company” or “UAHC Holding”), today announced the release of its unaudited first quarter report ending March 31, 2018 (“Quarterly Report”). The Quarterly Report can be found here. Additionally, the Company provided a summary of financial results from the report and an overview of recent operational highlights.

The company ranks among top 15 percent of recognized companies, including categories for Philadelphia, metro area, state and health industry

DrGreensoft’s new software makes managing patients easier than ever before. With all the necessary features needed to run a successful business, this software allows physicians to provide service in a professional manner, keep track of patients and employees, and improve overall medical care.

Ultragenyx Pharmaceutical Inc.(NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration(FDA) has cleared the Investigational New Drug (IND) application for DTX401, an adeno-associated virus vector based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences.

ltragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd(Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita® (burosumab-twza) for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older.